Flavonoids in Cannabis: A Comprehensive Report on Key Compounds

Introduction to Flavonoids in Cannabis

Flavonoids are a large family of plant secondary metabolites characterized by a 15-carbon skeleton arranged in two aromatic rings (A and B) linked by a 3-carbon bridge (forming a heterocyclic C-ring). This general C6-C3-C6 structure can be modified to form various subclasses (flavones, flavonols, flavanones, etc.), and often includes hydroxyl groups and sugar moieties. Flavonoids are ubiquitous in fruits, vegetables, and herbs, where they contribute to pigmentation (color in flowers and foliage), UV protection, and defense against pests. In the human diet and traditional medicine, many flavonoids are valued for their antioxidant, anti-inflammatory, and therapeutic properties.

Flavonoids in Cannabis: The cannabis plant (Cannabis sativa L.) produces an array of flavonoids alongside its cannabinoids and terpenes. These compounds can account for up to ~2.5% of the dry weight of cannabis flowers, although levels vary by plant part and strain. A comprehensive analysis found cannabis inflorescences (buds) contain roughly 0.1% flavonoids by weight, while the leaves contain higher levels (0.3–0.4%). At least 20 different flavonoids have been identified in cannabis, primarily flavones and flavonols (often as glycosides). Notable examples include the flavones apigenin and luteolin, their C-glycosides orientin, vitexin, and isovitexin, and the flavonols quercetin and kaempferol. Uniquely, cannabis also produces a set of prenylated flavones called cannflavins A, B, and C, which are not commonly found in other plants.

Cannabis flavonoids are thought to contribute to the plant’s therapeutic “entourage effect” by modulating the effects of cannabinoids. For example, flavonoids can inhibit certain cytochrome P450 enzymes involved in THC metabolism, potentially altering pharmacokinetics. They may also synergistically enhance desired effects or mitigate side effects of cannabinoids. In smoked or vaporized cannabis, many flavonoids remain bioactive and might act as antioxidants and anti-inflammatories, or even protect against harmful byproducts (by blocking conversion of pro-carcinogens in smoke). Given their diverse bioactivities, these compounds could influence outcomes in conditions like pain, anxiety, or neurodegenerative disorders when cannabis is used medicinally.

In this report, we focus on several key flavonoids found in cannabis: Cannflavin A, Cannflavin B, Cannflavin C, Apigenin, Luteolin, Kaempferol, Quercetin, Orientin, Vitexin, Isovitexin, Chrysin, Silymarin, and Baicalin. For each compound, we outline its chemical nature and mechanism of action, and review human studies (especially from the last 10 years) examining its effects on insomnia, pain, anxiety, epilepsy, or other central nervous system (CNS) disorders. Where applicable, we distinguish effects observed in the context of cannabis (with its complex mixture of compounds) versus isolated from other plants. We also note any known variation in their abundance between cannabis strains, and highlight pharmaceutical or nutraceutical applications of these flavonoids or their analogs.

Figure: Chemical structures of some representative flavonoids in cannabis – (a) Cannflavin A; (b) Cannflavin B; (c) the core flavone skeleton; (d) Luteolin (a flavone with multiple hydroxyl groups). Cannflavin A and B are prenylated flavones unique to cannabis.

Cannflavin A

Chemical Structure and Uniqueness: Cannflavin A is a prenylated flavone uniquely found in cannabis (and only rarely in a few other species). Chemically, it is a luteolin-based flavone structure with a C-5 isoprenyl (geranyl) substituent, giving it a larger, lipophilic side chain. This distinguishes it from common dietary flavones and likely underlies its potent bioactivity. Cannflavin A was first identified in the 1980s, alongside cannflavin B, in C. sativa extracts. It is considered one of the “cannflavins” – flavonoids essentially unique to cannabis. In the plant, cannflavin A is present in relatively low concentrations (trace levels, usually under 0.05% of dry weight), with exact amounts varying by strain and growing conditions. Studies indicate its accumulation is influenced not only by genetic background but also by environmental factors such as light and temperature.

Mechanisms of Action: Cannflavin A is best known for its powerful anti-inflammatory effects. It was shown in cell studies to inhibit the release of prostaglandin E2 with about 30 times the potency of aspirin (acetylsalicylic acid) on a weight-for-weight basis. Specifically, at extremely low concentrations (31 ng/mL), cannflavin A markedly reduced prostaglandin E2 production in human rheumatoid synovial cells – a level of inhibition roughly thirty-fold greater than aspirin’s effect in the same model. This action is attributed to cannflavin A’s inhibition of the arachidonic acid cascade; it can non-selectively block cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes, thereby suppressing the synthesis of pro-inflammatory mediators. Unlike NSAIDs which mainly target COX, cannflavin A’s dual COX/LOX inhibition might contribute to a broad anti-inflammatory profile without affecting endocannabinoid pathways. Recent computational studies also suggest cannflavin A may interact with kinase signaling (e.g. TAK1 in the NF-κB pathway) to reduce inflammation, although such mechanisms need experimental confirmation. Beyond anti-inflammatory effects, preliminary research indicates cannflavin A has neuroprotective and anti-cancer potential in vitro, but these are early findings.

Human Studies and Effects on CNS Conditions: To date, no clinical trials have tested isolated cannflavin A in humans. Its promising anti-inflammatory and analgesic effects are derived from ex vivo and animal studies. For example, in rodent models of inflammation and pain, cannflavin A (administered via extracts) produced significant anti-edema and analgesic responses. However, in human contexts, evidence is limited to the observation that whole cannabis extracts (which contain cannflavins alongside cannabinoids) have anti-inflammatory benefits. Some researchers speculate that cannflavin A contributes to the pain-relieving properties of cannabis by targeting inflammatory pain pathways distinct from the cannabinoid system. This has led to interest in developing cannflavin-based therapies for conditions like arthritis or migraines, where peripheral inflammation plays a role in pain. Notably, in 2019 scientists in Canada identified the genes responsible for cannflavin biosynthesis and expressed them in yeast, a step towards producing cannflavin A at scale for pharmacological testing. As of now, no human trials on insomnia, anxiety, or epilepsy have been conducted with cannflavin A. Any sedative or anxiolytic effect in cannabis use is more likely due to cannabinoids and terpenes; cannflavin A’s role would be indirect (through anti-inflammatory or possibly neuroprotective support).

Cannabis vs. Other Sources: Cannflavin A is essentially a cannabis-derived molecule. Apart from cannabis, it has only been identified in trace amounts in one other plant (a rare species in the Phrymaceae family). Therefore, its effects have mostly been considered in the context of cannabis or as an isolated compound in experimental models. In cannabis, cannflavin A co-occurs with THC, CBD, and other flavonoids, which could modulate its bioavailability or effects. It’s worth noting that typical cannabis consumption methods (smoking, vaporizing) may degrade flavonoids due to heat; thus, whether cannflavin A reaches systemic circulation in meaningful amounts from smoking is unclear. Some medicinal cannabis preparations (e.g. tinctures or edibles) might preserve cannflavin A better, potentially contributing to long-term anti-inflammatory benefits for chronic pain patients. By contrast, one would not encounter cannflavin A through diet or common herbs (unlike apigenin or quercetin which are abundant in foods).

Strain Variation: The content of cannflavin A can vary widely between cannabis strains and even individual plants. One study found up to a tenfold difference in cannflavin levels among individual plants of the same variety. Generally, fiber-type hemp and certain chemovars bred for high flavonoid content may express more cannflavin A, whereas THC-rich drug strains might have less. Environmental stress (such as high UV exposure) can also upregulate cannflavin A production as part of the plant’s defense response. Currently, breeders and researchers are exploring whether specific “high-flavonoid” cannabis lines could be developed to maximize cannflavin content for anti-inflammatory applications.

Pharmaceutical Developments: There is no approved drug containing cannflavin A yet. However, the remarkable COX/LOX inhibition of cannflavin A has attracted interest in it as a lead compound for novel anti-inflammatory or analgesic drugs. Researchers have suggested that a cannflavin-based medication could provide pain relief through a different mechanism than opioids or NSAIDs, potentially useful for inflammatory pain conditions. The main hurdle is obtaining sufficient cannflavin A – natural cannabis yields are low, so biotechnological production (yeast biosynthesis or chemical synthesis) is being pursued. Any future “cannflavin” drug would need thorough testing for safety and efficacy in humans. For now, cannflavin A remains a promising molecule seen largely in preclinical research.

Cannflavin B

Chemical Structure: Cannflavin B is another prenylated flavone found in Cannabis sativa. Structurally it is closely related to cannflavin A, sharing the geranyl side-chain but differing in the pattern of hydroxyl and methoxy substitution on the flavone backbone. Cannflavin B was discovered alongside cannflavin A in the 1980s and similarly considered unique to cannabis. It is slightly smaller in molecular weight (cannflavin B has formula C_21H_20O_6 vs. cannflavin A’s C_26H_28O_6), indicating cannflavin B lacks some methyl/hydrocarbon extensions present in A. Like A, it is present in cannabis in trace amounts. Both cannflavin A and B are localized in cannabis leaves and flowers, likely in glycosylated forms or bound to plant glycosides.

Mechanism of Action: Cannflavin B is also reported to have anti-inflammatory properties, though it is less studied than cannflavin A. Early research showed cannflavin B could inhibit prostaglandin and leukotriene synthesis, albeit with somewhat lower potency than cannflavin A. It appears to work via a similar mechanism (inhibition of COX and possibly 5-LOX enzymes), given its structural similarity. There is evidence that cannflavin B’s anti-inflammatory effect is still significant – one source notes cannflavin B also exceeded aspirin’s potency in an ex vivo inflammatory model. It may contribute to reducing lipid peroxidation and free radical damage as well. Beyond inflammation, little specific data exists on cannflavin B’s pharmacodynamics. It is plausible that it shares cannflavin A’s neuroprotective and analgesic tendencies, but direct studies are scarce.

Human Studies: No human studies have been conducted on cannflavin B alone. Given its co-occurrence with cannflavin A, any investigation of “cannflavin extracts” (for example, in cell studies or animal tests of cannabis leaf extracts) would include both. For instance, a crude cannabis extract used in a model of inflammation would naturally contain a mix of A and B (and perhaps C), so attributing effects solely to B is difficult. There is currently no clinical data on cannflavin B for insomnia, pain, anxiety, or epilepsy. As such, our understanding of its role comes from basic science.

However, it’s reasonable to assume cannflavin B contributes alongside cannflavin A to the overall anti-inflammatory impact of cannabis. If a patient uses a non-psychoactive cannabis preparation (like a topical or high-CBD extract) for inflammation or pain, both cannflavin A and B might be working in concert to inhibit inflammatory mediators. No known sedative or anxiolytic effect is associated with cannflavin B in isolation. Any CNS-related benefit would likely stem from reduction of inflammation (which in chronic pain or neuroinflammatory conditions could translate to symptom relief).

Cannabis Context vs. Other Plants: Cannflavin B is essentially exclusive to cannabis. Unlike common flavonoids, one would not encounter cannflavin B from dietary sources or typical herbs. Thus, its effects are normally experienced only when consuming cannabis or cannabis-derived products. In cannabis, B is always accompanied by A (they share a biosynthetic pathway and often similar levels). The “entourage” interplay is relevant: cannflavin B might modulate or complement cannabinoid activity – for example, by providing peripheral anti-inflammatory action that synergizes with cannabinoids’ central analgesic effects. Outside of cannabis, there is no evidence of cannflavin B use.

Strain Variation: Similar to cannflavin A, levels of cannflavin B vary among strains. Some analytical chemistry studies have profiled flavonoid content in different chemotypes. They often find cannflavin B present in low µg/g quantities, sometimes even undetectable in certain samples. High-B levels tend to correlate with high-A levels (since both derive from the same branch of the phenylpropanoid pathway in the plant). Environmental stressors that boost cannflavin A likely also boost B. Breeding efforts for high cannflavins would target both A and B. One study noted that across individual plants, cannflavin B could fluctuate up to tenfold, suggesting significant phenotypic plasticity.

Pharmaceutical and Research Notes: There are no pharmaceutical analogs of cannflavin B in use. It remains a research compound. Some patents and biomedical research have mentioned “cannflavin-enriched extracts” as potential therapeutic agents (for example, as anti-inflammatory supplements or topical analgesics), but these are not yet realized in the market. As interest in non-opioid pain relievers grows, cannflavin B, together with A, is on the radar of drug developers. Any future development would likely combine both major cannflavins for synergistic effect, unless a specific derivative of B proves superior. Overall, cannflavin B is a piece of the cannabis phytochemical puzzle that reinforces the plant’s anti-inflammatory reputation, though by itself it is not well-characterized in humans.

Cannflavin C

Chemical Profile: Cannflavin C is the third characterized cannabis flavonoid in the cannflavin group. It was identified more recently (in the 1990s) in cannabis plant material. Chemically, cannflavin C is also a prenylated flavone, similar in core structure to A and B, but with yet another distinct pattern of substitutions. The exact structure of cannflavin C has been reported as a derivative of apigenin or luteolin with a geranyl and malonyl substitution (some sources describe it as a malonylated glucoside of cannflavin A). This could mean that cannflavin C is not a free aglycone but a modified form stored in the plant. Indeed, one study suggested cannflavin C might be an artifact or a conjugated form that can convert to cannflavin A/B under certain conditions. Regardless, it is considered a member of the cannabis-specific flavones.

Mechanisms and Bioactivity: Cannflavin C is the least studied of the trio. There is limited data on its bioactivity. Given its structural kinship with A and B, it is presumed to have anti-oxidant and anti-inflammatory properties. One report noted cannflavin C exhibited antioxidant activity in a laboratory assay. It likely contributes to the free-radical-scavenging capacity of cannabis extracts. Some analyses include cannflavin C when quantifying total “cannflavins,” implying it co-inhibits inflammatory mediators. However, specific assays of COX/LOX inhibition by cannflavin C have not been well-publicized. It is possible that cannflavin C, if it is a glycoside, might be less active until it is metabolized (e.g., gut bacteria or heat could cleave it to an active form).

Human Evidence: There are no human or clinical studies focusing on cannflavin C. Its presence in cannabis was confirmed, but beyond that, it remains an academic curiosity. Human consumption of cannabis would include cannflavin C, but any effects are indistinguishable from those of A, B, and other components. For conditions like pain or anxiety, nothing specific is known about cannflavin C’s role. If anything, it would only act in tandem with cannflavin A/B to reduce inflammation. No trials for insomnia or epilepsy exist. Thus, from a human perspective, cannflavin C is currently a minor component with potential but unproven effects.

Cannabis Context: As with A and B, cannflavin C is unique to cannabis (hence the naming). In the plant, its levels are very low. One phytochemical screening detected cannflavin C in some cannabis samples but not others, suggesting it might appear under certain growth conditions or in certain genotypes. If cannflavin C is indeed a conjugated form, it might accumulate in freshly harvested material and then decline (or transform) with curing or processing. Most commercial cannabis analysis labs do not routinely quantify cannflavin C. Therefore, little is known about strain-to-strain variation specifically for C.

Pharmaceutical Aspect: There are no known drugs or supplements featuring cannflavin C. It has not been a focus for drug development, likely because it is even harder to obtain in quantity than A or B. Should A and B prove useful, cannflavin C might gain interest as well, but currently it is scientifically niche. Some biotechnology efforts aim to express the entire cannflavin biosynthetic pathway (which would produce A, B, and C together) in yeast or other systems. This could inadvertently provide more cannflavin C to study. Until then, cannflavin C remains the least understood of the cannabis flavonoids.

Summary: In summary, the cannflavins (A, B, C) are a distinctive aspect of cannabis chemistry with strong anti-inflammatory actions demonstrated in preclinical models. Their relevance to human health lies mostly in their potential as novel anti-inflammatory agents and their possible contribution to cannabis’s analgesic effects. All three lack direct clinical evidence, but their presence in cannabis products could enhance anti-inflammatory outcomes. As research continues, we may see these flavonoids (particularly A and B) explored as leads for pain relief medications that do not carry the side effects of NSAIDs or opioids.

Apigenin

Chemical Structure: Apigenin is a well-known flavonoid of the flavone subclass, with the chemical formula C_15H_10O_5. Structurally it is 4′,5,7-trihydroxyflavone – a basic flavone backbone bearing hydroxyl groups at positions 5 and 7 on the A-ring and 4′ on the B-ring. Apigenin is widely distributed in the plant kingdom; it is the principal flavonoid in chamomile flowers (Matricaria chamomilla) and is found in parsley, celery, and other herbs. In cannabis, apigenin has been identified as one of the flavones present in both free (aglycone) form and as glycosides. It does not have the cannabis-specific prenylation that cannflavins do; it’s a “normal” flavone also obtainable from diet. Cannabis plants contain apigenin in modest amounts (one analysis found apigenin and its glycosides in leaves and flowers, contributing to the ~0.1–0.2% flavonoid fraction). In cannabis smoke, apigenin can be delivered intact in small quantities.

Mechanisms of Action: Apigenin is known for a variety of pharmacological effects, particularly on the central nervous system. Notably, apigenin is a natural anxiolytic: it can bind to benzodiazepine sites on the GABA_A receptors in the brain. By selectively binding to the benzodiazepine receptor subunits (at the interface of the α and β subunits of GABA_A receptors), apigenin exerts a mild tranquilizing effect without strong sedation. This mechanism is similar in kind to benzodiazepine drugs (which enhance GABAergic transmission), though apigenin is much weaker in effect. In addition, apigenin has been shown to interact with estrogen receptors, particularly exhibiting agonist activity at the β-estrogen receptor. In cannabis smoke, apigenin is thought to be one of the main “estrogenic” constituents, though the clinical significance of that is unclear. Beyond receptor binding, apigenin has robust anti-inflammatory and antioxidant actions. It inhibits NF-κB activation and reduces pro-inflammatory cytokine release in microglia and other immune cells, which could contribute to neuroprotective effects. It also scavenges free radicals and upregulates antioxidant enzymes. Apigenin has demonstrated anti-cancer properties (for example, inducing cell cycle arrest in certain tumor cells) and even modulates enzymes like monoamine oxidase and cyclooxygenase to a mild extent in some studies.

Relevantly, apigenin’s GABA_A receptor activity underpins its sedative (sleep-promoting) and anxiolytic properties observed in traditional remedies like chamomile tea. It is often cited as the “primary anxiolytic agent” in chamomile. At higher doses, apigenin can also have muscle-relaxant and mild analgesic effects, again likely via central nervous system depression pathways.

Human Studies (2015–2025) – Anxiety, Insomnia, CNS: A growing body of human research has examined apigenin’s effects, often via chamomile extracts which contain apigenin as a key component. One significant trial was a randomized, placebo-controlled study of chamomile extract in generalized anxiety disorder (GAD). In that study, patients with moderate-to-severe GAD took 1,500 mg of chamomile extract (standardized to apigenin content) daily for 8-12 weeks. Chamomile treatment resulted in a significant reduction in anxiety symptoms (as measured by the Hamilton Anxiety Rating) compared to placebo. Importantly, long-term use was safe and helped maintain lower anxiety levels, though it did not dramatically prevent relapse when treatment stopped. The researchers noted chamomile’s effects were modest but tangible, supporting its use as a supplemental anxiolytic. Apigenin is believed to be a major contributor to this outcome, given its GABA_A-modulating effect, although other components of chamomile may also play a role.

In the context of sleep (insomnia), apigenin’s sedative effect has been explored in a few human studies. For example, a trial in elderly people with poor sleep quality found that chamomile extract (rich in apigenin) significantly improved sleep quality scores over 4 weeks. Similarly, a small study involving postpartum women reported better sleep and mood in those who drank chamomile tea daily (versus control). While these are indirect evidence (via a whole herb), they align with apigenin’s known calming effects. Users often subjectively report chamomile tea (apigenin ~1-2% of chamomile by weight) helps them relax and fall asleep more easily.

Beyond anxiety and sleep, apigenin has shown potential in other CNS-related areas. A noteworthy example is a 2016 pilot trial where apigenin (via chamomile) was tested as an adjunctive therapy in depression and anxiety in diabetics – it was associated with improved self-reported anxiety and quality of life. Moreover, apigenin is under investigation for neurodegenerative diseases: while human data is scarce, animal models suggest it may protect neurons from damage (e.g. apigenin improves memory and reduces amyloid burden in mouse models of Alzheimer’s disease). There was also a long-term human trial initiated in 2016 looking at chamomile (apigenin) for GAD relapse prevention, indicating continued clinical interest in apigenin’s therapeutic value.

Cannabis vs. Other Sources: In cannabis, apigenin is present but in relatively low concentrations compared to major cannabinoids. Therefore, when consuming cannabis, any apigenin-induced effects (like anxiolysis or sedation) are likely subtle and potentially overshadowed by THC’s psychoactive impact or myrcene’s sedative terpene effect. However, apigenin could contribute to the overall calming effect of certain cannabis strains, especially those touted for anxiety relief or insomnia. It may also synergize with THC/CBD: for instance, by binding to GABA_A receptors, apigenin might complement CBD’s anxiolytic effect or offset some excitatory side effects of THC. Another consideration is that apigenin in cannabis smoke might act as a chemoprotective agent, as flavonoids can reduce the formation of harmful metabolites in smoke.

Outside of cannabis, apigenin’s effects are more readily obtained from dietary and herbal sources. Chamomile tea, in particular, is a popular remedy for anxiety and insomnia specifically because of apigenin. Human studies using chamomile essentially demonstrate apigenin’s efficacy in a real-world setting. Thus, we can say apigenin’s anxiolytic and sedative properties are well-established outside of cannabis. Within cannabis, it’s one component of the broader phytochemical profile. Unlike cannflavins, apigenin is not unique to cannabis, so its effects do not fundamentally differ whether it comes from cannabis or another plant. The main difference is dosage and context: a cup of chamomile might deliver ~ apigenin in tens of milligrams, whereas a typical cannabis joint contains far less apigenin (perhaps a few milligrams at most). Therefore, while apigenin is pharmacologically active, one likely wouldn’t rely on smoking cannabis as a primary source of apigenin for treating anxiety – dedicated chamomile or apigenin supplements would be more effective for that specific purpose.

Pharmaceutical/Nutraceutical Use: Apigenin itself is not an approved pharmaceutical, but its presence in widely used herbal remedies (like chamomile extracts) is notable. Chamomile is available as an over-the-counter supplement for anxiety and sleep support, standardized to apigenin content (often ~1.2% apigenin in extracts). There is ongoing research into using apigenin or derivatives as cognitive enhancers or anxiolytic agents in aging (given some hints that it may promote adult neurogenesis and protect against inflammation in the brain). No synthetic analog of apigenin has yet been developed as a drug, likely because apigenin itself has low toxicity and decent bioavailability for a flavonoid. One limitation is that apigenin, like many flavonoids, can undergo rapid metabolism (conjugation) in the gut and liver, which might reduce its active levels in the brain. Formulations to improve its CNS delivery (e.g. nanoparticle carriers) are being studied in the context of neurodegenerative disease.

In summary, apigenin is a flavonoid in cannabis that likely contributes a mild anxiolytic and anti-inflammatory effect, though in cannabis its impact is subtle compared to other constituents. Human studies (mostly via chamomile) confirm apigenin’s potential to reduce anxiety and improve sleep, making it a notable component when considering the overall therapeutic profile of cannabis for conditions like anxiety or insomnia.

Luteolin

Chemical Structure: Luteolin is a flavone very similar to apigenin, but with an extra hydroxyl group. Chemically it is 3′,4′,5,7-tetrahydroxyflavone (apigenin has three – luteolin has an additional OH at the 3′ position on the B-ring). Its formula is C_15H_10O_6. This additional hydroxyl makes luteolin a strong antioxidant and perhaps slightly more polar. Luteolin is common in many plants – it gives the yellow color to things like celery leaves, perilla, and some peppers. In cannabis, luteolin and its glycosides have been identified among the flavonoid fraction. A cannabis plant may contain luteolin as the free aglycone and also as C-glycosides (notably orientin and isoorientin, which are luteolin-8-C-glucoside and luteolin-6-C-glucoside respectively). Luteolin has been confirmed in cannabis leaf extracts and inflorescences in multiple studies. It is one of the main flavones in hemp varieties, often found alongside apigenin.

Mechanisms of Action: Luteolin is distinguished by its potent anti-inflammatory and neuroprotective mechanisms. It is a well-studied inhibitor of mast cells and microglia – cells involved in allergic and inflammatory responses in the brain. Luteolin has been shown to inhibit the release of histamine and pro-inflammatory cytokines from mast cells, and to reduce activation of microglial cells (the brain’s immune cells). This anti-inflammatory effect is mediated through suppression of NF-κB and other signaling pathways (like AP-1), and by reducing the production of inflammatory mediators (e.g. IL-6, TNF-α). Luteolin is also a strong antioxidant: with four hydroxyl groups, it can chelate metal ions and neutralize free radicals efficiently. It protects neurons from oxidative stress and excitotoxicity in various models. Moreover, luteolin has been noted to inhibit certain kinase pathways – for instance, it can inhibit glycogen synthase kinase-3β (GSK-3β) and casein kinase, which are implicated in neurodegenerative disease processes.

In terms of CNS effects, luteolin is not sedative like apigenin; instead it might be considered more neuroprotective and anti-excitatory. Some studies suggest luteolin modulates glutamate receptors and can cross the blood-brain barrier to exert central effects. It does not directly bind GABA_A receptors with high affinity (unlike apigenin), but it might indirectly have anxiolytic or cognitive-enhancing effects via reducing neuroinflammation. Luteolin also shows anti-convulsant potential in animal models – it can raise seizure threshold and reduce seizure severity in rodents, likely by dampening neuroinflammation and oxidative damage in the brain. Additionally, luteolin has been investigated for its anti-cancer properties (especially brain tumors due to its brain permeability) and for improving metabolic disorders.

Human Studies (Last 10 Years): There have been a few exploratory human studies and clinical trials involving luteolin, though not many large-scale ones. One area is neurodevelopmental disorders: an open-label pilot study in children with autism spectrum disorder (ASD) tested a dietary supplement containing luteolin (around 100 mg/day from a purified formulation) and reported improvements in some behavioral measures. In that study, luteolin (often combined with quercetin and a fatty acid PEA as in the supplement) was associated with reduced irritability and better adaptive behaviors in ASD children over a few months. While it was not placebo-controlled, it hinted at luteolin’s ability to ameliorate neuroinflammatory symptoms (ASD is hypothesized to involve inflammation and allergy-like neuroimmune activation, which luteolin could calm due to mast cell stabilization). A subsequent small case series also suggested benefits of a luteolin formulation in ASD, though more rigorous trials are needed.

In the realm of cognitive function and neurodegeneration, there are currently no major published human trials specifically of luteolin. However, epidemiological data provides some indirect support: luteolin is one of the flavonoids (along with kaempferol and quercetin) whose high dietary intake correlates with slower cognitive decline in older adults. A 2019-2020 analysis from the Rush University Memory and Aging project found that seniors consuming the most luteolin (from foods like peppers, spinach, etc.) had better cognitive scores over time compared to those consuming the least, suggesting luteolin-rich foods might be protective against dementia. Though this is observational, it aligns with luteolin’s known neuroprotective actions in animal models of Alzheimer’s (where it reduces amyloid pathology and inflammation).

For anxiety or insomnia, human evidence is sparse. Luteolin itself hasn’t been a primary target for clinical anxiety trials. It’s possible that any calming effect of luteolin goes hand-in-hand with overall health improvements. For example, a study of a multi-herb extract for stress might include luteolin-containing herbs (like Perilla or Chamomile) and note stress reduction, but isolating luteolin’s contribution is hard. One can note that luteolin’s presence in passionflower (Passiflora) or chamomile could contribute to those herbs’ anxiolytic effects, but apigenin/vitexin are considered more active for sedation in those plants.

Interestingly, luteolin has been tried in combination with palmitoylethanolamide (PEA) as a therapy for chronic neurological diseases (PEA+luteolin is a supplement used in some countries for neuroinflammation). A 2020 review noted that ultra-micronized PEA with luteolin has shown promise in conditions like diabetic neuropathy and post-stroke syndrome, improving neuropathic pain and cognitive function in some small studies. This suggests luteolin could also help with certain types of pain, especially those with inflammatory components. In fact, a recent randomized pilot trial (2022) in type 2 diabetics found that 8-week supplementation with a combination including luteolin improved neuropathic pain scores and quality of life (though luteolin was not the sole ingredient).

Cannabis vs. Other Sources: In cannabis, luteolin is one of many flavonoids and likely contributes to the plant’s anti-inflammatory and neuroprotective profile. If someone uses a high-CBD, high-flavonoid cannabis extract for something like pediatric epilepsy or anxiety, luteolin could be a supportive factor by reducing neuroinflammation associated with seizures or stress. However, the amount of luteolin delivered in typical cannabis use is much less than one would get from dietary supplements or flavonoid-rich foods. Thus, while cannabis contains luteolin, those seeking luteolin’s benefits typically look to other sources (like specialized supplements such as NeuroProtek which contains luteolin, or luteolin-rich diets).

One clear difference: in Passionflower (Passiflora incarnata), an herbal anxiolytic, luteolin is present mostly as glycosides (orientin, isoorientin), and that herb has shown anxiolytic effects in humans (reducing anxiety before surgery and in generalized anxiety in some trials). Those effects are often attributed to the combined action of flavonoids (including luteolin derivatives and others) on GABA and oxidative stress. In cannabis, luteolin might have similar biochemical actions, but its impact is subtle compared to cannabinoids. For example, a high-THC strain might cause anxiety in some users; if luteolin is present, it might marginally counteract that by dampening microglial activation or oxidative stress from THC metabolism, but it won’t prevent acute THC-induced anxiety outright.

In summary, luteolin’s effects in cannabis are more about long-term health influence (anti-inflammatory, neuroprotective) rather than immediate psychoactive effects. Outside cannabis, luteolin is actively being explored as a therapeutic nutraceutical for brain health, allergy, and inflammation.

Pharmaceutical/Clinical Use: Luteolin is not a prescription drug, but it is available in some dietary supplements. For example, a product called LutiMax or NeuroProtek (formulated by Dr. T. Theoharides) provides luteolin (often 100–200 mg per day) for conditions like autism, ADHD, or mast cell-related disorders, based on the rationale of reducing neuroinflammation and mast cell activation. Some small trials or case studies (as mentioned in ASD) have used these formulations with encouraging results. There is also research into using luteolin in combination with quercetin and PEA for long COVID or post-viral inflammation to mitigate neuroinflammatory symptoms. No major side effects have been reported for luteolin at these doses, though very high doses could potentially affect thyroid function (as flavonoids can interfere with thyroid peroxidase in vitro).

From a drug development perspective, luteolin is being investigated in preclinical models of Alzheimer’s and Parkinson’s diseases. Given its ability to activate transcription factor Nrf2 (promoting antioxidant defenses) and inhibit pro-inflammatory pathways, it is a candidate for slowing neurodegeneration. However, issues of bioavailability and crossing the BBB in sufficient amounts remain. Some newer delivery methods (like luteolin nanoparticles or luteolin prodrugs) are under research.

In conclusion, luteolin is a potent flavonoid present in cannabis that primarily offers anti-inflammatory and neuroprotective benefits. Human clinical evidence suggests it can help reduce anxiety-like symptoms in certain contexts (like autism or possibly inflammatory conditions) and might protect cognitive function in aging. In cannabis use, it likely plays a supportive (entourage) role in reducing inflammation and oxidative stress, which could be beneficial for chronic pain or neurodegenerative patients using medical cannabis. It does not appear to directly induce sleep or calm in the acute sense, but it supports the long-term CNS health.

Kaempferol

Chemical Structure: Kaempferol is a flavonol – structurally similar to quercetin but with one fewer hydroxyl group. Its IUPAC name is 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one. In simpler terms, it has hydroxyls at 3, 5, and 7 positions (and a 4′-hydroxy on the B-ring if considering tautomeric form; kaempferol is often described with four OH groups as well, depending on numbering). Actually, kaempferol’s typical description is 3,4′,5,7-tetrahydroxyflavone, indicating OH groups at 3, 5, 7, and 4′. (Quercetin has an additional OH at 3′). Kaempferol is widely present in fruits and vegetables such as berries, kale, tea, broccoli, and grapefruit. In cannabis, kaempferol and its glycosides (like astragalin = kaempferol-3-glucoside) have been identified as part of the flavonol profile. In one analysis of commercial cannabis, kaempferol and quercetin were the predominant flavonols detected. The absolute amount is small (perhaps on the order of tens of micrograms per gram of plant). Kaempferol often coexists with quercetin in the plant and is somewhat more stable (because quercetin’s extra OH makes it more prone to oxidation).

Mechanisms of Action: Kaempferol exerts a broad range of biological activities, many overlapping with quercetin’s but somewhat less potent in certain assays. Key mechanisms include: Antioxidant action – kaempferol scavenges reactive oxygen species and upregulates the body’s antioxidant enzymes. Anti-inflammatory effects – it inhibits inflammatory enzymes (like COX-2, iNOS) and downregulates NF-κB pathway activity, thereby reducing cytokine production. Kaempferol has been shown to inhibit TNF-α and IL-1β levels in activated microglia and macrophages, indicating a dampening of inflammatory responses. It also can inhibit toll-like receptor 4 (TLR4) signaling and the activation of NLRP3 inflammasome, which are involved in chronic inflammation.

Kaempferol may influence pain pathways as well. In preclinical studies, kaempferol had analgesic effects in models of neuropathic pain: for instance, it reduced diabetic neuropathic pain in rats by attenuating oxidative stress and inflammatory signaling in nerves. Mechanistically, kaempferol appears to modulate the TRPV1 and opioid receptors to some extent, which might contribute to analgesia. It also shows neuroprotective properties: in models of neurodegenerative diseases (like Parkinson’s and Alzheimer’s), kaempferol can protect neurons by reducing apoptosis and protein aggregation, attributed to its anti-oxidative and anti-apoptotic functions. Some evidence points to kaempferol activating AMPK (an energy-sensing enzyme) and thereby promoting neuronal survival pathways.

Additionally, kaempferol has anxiolytic and antidepressant-like effects in animals. It was reported that kaempferol administration in mice produced reductions in anxiety-like behavior and had an antidepressant-like effect in forced swim tests, potentially through modulation of monoaminergic systems and BDNF expression (though these effects are mild compared to classic anxiolytics).

Human Studies and Clinical Evidence: Direct human studies on kaempferol specifically are limited, as it’s usually obtained as part of a diet or plant extract rather than given in isolation. However, as part of dietary flavonols, kaempferol has been linked to positive health outcomes. A notable epidemiological study (published in 2019 in Neurology) found that higher dietary intake of kaempferol was associated with a lower risk of developing Alzheimer’s dementia. Specifically, those in the highest quintile of kaempferol consumption had ~50% reduced risk of dementia compared to the lowest quintile. Moreover, a 2022 analysis (in Neurology or JAMA Network Open) showed that high intake of kaempferol was associated with a slower rate of global cognitive decline in older adults. While these are observational findings, they align with kaempferol’s neuroprotective profile and suggest that long-term consumption of kaempferol-rich foods might benefit brain aging.

In terms of pain and inflammation, kaempferol has not been separately trialed in humans, but we have hints from related studies. For example, kaempferol is one of the active flavonoids in ginger and green tea, which have shown some efficacy in pain and arthritis management. A small RCT in 2017 tested a combination of flavonoids (including kaempferol, quercetin, and others from propolis extract) in rheumatoid arthritis patients and found improvements in disease activity and inflammatory markers. It’s hard to ascribe the effect to kaempferol alone, but as part of the flavonoid mix, it likely contributed to the observed reduction in morning stiffness and pain. Kaempferol’s capacity to reduce inflammatory pain was further evidenced by animal-to-human translation: rodent studies show relief in neuropathic pain, and some nutraceuticals marketed for joint health include kaempferol-containing ingredients (though formal clinical trials are scant).

For anxiety or insomnia, there is no direct clinical trial with kaempferol. However, kaempferol is present in St. John’s Wort and Ginkgo biloba extracts (both contain multiple flavonols), which have been used for anxiety/mood issues. Any effect from those could partially involve kaempferol’s MAO-inhibitory properties (kaempferol can mildly inhibit monoamine oxidase, theoretically raising monoamine neurotransmitters). But again, isolating kaempferol’s role is difficult.

One interesting area is cardiometabolic health: some human trials have looked at flavonol supplements (quercetin/kaempferol mix) for metabolic syndrome. These often note reduced blood pressure and improved endothelial function, which indirectly could affect brain health (better circulation). But those are beyond our CNS focus.

Cannabis Context: In cannabis, kaempferol likely contributes to antioxidant and anti-inflammatory effects, especially peripherally. For a patient using cannabis for arthritis or inflammatory pain, kaempferol (along with quercetin) in the plant might help reduce local inflammation and oxidative stress, potentially enhancing pain relief beyond what cannabinoids alone do. Cannabis users don’t typically feel an acute effect from kaempferol (it’s not psychoactive), but its presence might be one factor in why some strains feel “clear-headed” or less fatiguing – flavonols like kaempferol can support mitochondrial function and reduce the oxidative burden of THC metabolism.

There is also a possibility that kaempferol could modulate cannabinoid activity: some flavonols can inhibit FAAH (the enzyme that breaks down endocannabinoids) and P450 enzymes that metabolize THC/CBD. If kaempferol has any such effect, it could slightly prolong endocannabinoid action or alter the plasma levels of cannabinoids. This hasn’t been specifically studied for kaempferol, but quercetin and kaempferol are known P450 inhibitors in vitro, so co-consumption might increase cannabinoid bioavailability.

Kaempferol’s role in epilepsy or CNS disorders via cannabis is not documented. If anything, by reducing systemic inflammation, it could help create a more favorable condition for neurological health.

Pharmaceutical Potential: Kaempferol itself is not a drug, but its strong therapeutic indications have made it a molecule of interest. No dedicated kaempferol supplement is widely marketed because most supplements focus on quercetin (which often contains some kaempferol naturally). However, as mentioned, diets high in kaempferol (e.g., the MIND diet) are being actively recommended for brain health due to supportive evidence.

In the pharmaceutical realm, kaempferol derivatives are being explored. For instance, scientists are investigating kaempferol analogs that might better cross the blood-brain barrier or have higher potency. Kaempferol has relatively good oral bioavailability for a flavonoid (~20-30%) and a half-life that allows some accumulation. It’s generally safe; humans consuming high-kaempferol diets haven’t reported adverse effects specifically attributable to it. Thus, it holds promise as a nutraceutical for neuroprotection, potentially delaying onset of neurodegenerative diseases or cognitive decline.

Additionally, kaempferol is being studied for psychiatric disorders like depression: A 2022 preclinical study suggested kaempferol produced antidepressant-like effects in stressed mice by modulating the HPA axis and neurotrophic factors. This could pave the way for trials in humans with depression or anxiety, especially for those with inflammation-linked depression.

In summary, kaempferol is a flavonoid in cannabis that offers antioxidant, anti-inflammatory, and neuroprotective benefits. Human evidence (mostly observational or in combination supplements) associates it with reduced inflammation and possibly reduced risk of dementia, as well as improvements in rheumatoid arthritis symptoms when supplemented. While one wouldn’t use cannabis specifically to get kaempferol, its presence enhances the medicinal profile of cannabis. As research continues, kaempferol might emerge as a key nutraceutical for protecting the brain and alleviating inflammatory pain.

Quercetin

Chemical Structure: Quercetin is one of the most abundant dietary flavonoids and belongs to the flavonol subclass. Its structure is 3,3′,4′,5,7-pentahydroxyflavone – essentially the same backbone as kaempferol but with an extra hydroxyl at the 3′ position on the B-ring. The formula is C_15H_10O_7. Quercetin is widely found in apples, onions, berries, grapes, and many seeds and nuts. In cannabis, quercetin (and its glycosides like rutin = quercetin-3-rutinoside) has been identified consistently. It is often reported as one of the highest-concentration flavonoids in cannabis (though still only on the order of 0.01–0.1% by weight). Quercetin’s presence in cannabis smoke was confirmed and it appears to “survive” combustion to a degree, meaning smokers can inhale quercetin. Quercetin is also notable for being a pigmented flavonoid (yellow), and along with other flavonols, it contributes to the coloration of cannabis leaves (especially when leaves turn yellowish in late flowering, that can be partly flavonols).

Mechanisms of Action: Quercetin has a very broad pharmacological profile. Some key mechanisms relevant to CNS and inflammation include:

• Antioxidant: Quercetin is a powerful scavenger of free radicals (with five OH groups, it can donate protons/electrons to neutralize radicals). It also chelates metal ions that catalyze oxidative reactions. It elevates levels of antioxidant enzymes like glutathione peroxidase and catalase in cells. This antioxidant property is thought to underlie many of its protective effects in different organ systems.
  
  
• Anti-inflammatory: Quercetin inhibits multiple pathways of inflammation. It can directly inhibit the activity of NF-κB, reducing the transcription of pro-inflammatory genes (TNFα, IL-6, IL-1β, COX-2). It also suppresses MAPK pathways (like p38 kinase) in immune cells, leading to lower cytokine release. Quercetin stabilizes mast cells, thereby reducing histamine release (hence its use in allergies). In microglia and macrophages, quercetin decreases the production of nitric oxide (by downregulating inducible NO synthase) and prostaglandins (by modulating COX and lipoxygenase). Another interesting mechanism is quercetin’s inhibition of the NLRP3 inflammasome, which plays a role in chronic inflammation and neuroinflammation.
  
  
• Analgesic: Through its anti-inflammatory actions, quercetin has demonstrated analgesic effects in inflammatory pain models. It also can modulate ion channels involved in pain sensation. For example, quercetin inhibits voltage-dependent sodium channels and certain potassium channels in neurons, which might contribute to a direct analgesic effect. It’s been observed to reduce neuropathic pain behaviors in rodents by mitigating oxidative stress in nerves and blocking pain neurotransmitter release.
  
  
• Anxiolytic/Antidepressant: Quercetin influences neurotransmitter systems to some extent. It has a mild inhibitory effect on monoamine oxidase (particularly MAO-A), which could lead to increased levels of serotonin and norepinephrine in the brain. In mice, chronic quercetin administration showed reduced anxiety-like behavior and depression-like behavior, possibly due to restoration of hippocampal BDNF levels and reduced neuroinflammation. Quercetin also interacts with GABA_A receptors at high concentrations, though not as strongly as apigenin or chrysin. There is some evidence that quercetin may bind to the benzodiazepine site (as a partial agonist) which might confer a mild anxiolytic effect – but this is likely only at high doses that are not typically achieved through diet.
  
  
• Anti-seizure (inconsistently): Quercetin has had mixed results in seizure models – some studies show it can prolong latency to seizure (perhaps via antioxidant protection), while others suggest high doses of quercetin could be pro-convulsant due to certain pro-oxidant interactions or P450 interactions. There isn’t a clear consensus, and no human epilepsy data exists for quercetin.
  
  
• Neuroprotective: Quercetin crosses the blood-brain barrier (though its metabolites do so to a greater extent). Once in the brain, its antioxidant and anti-inflammatory actions help protect neurons from toxin-induced damage. It also can promote mitochondrial biogenesis through activating SIRT1/PGC-1α pathways. In models of Alzheimer’s, quercetin reduced amyloid plaque formation and improved cognitive function in rodents, partly by chelating iron and copper (which contribute to amyloid aggregation) and by reducing microglial activation.
  
  

Human Studies – Anxiety, Pain, CNS (2015–2025): A number of human clinical studies have used quercetin, often as a nutraceutical for various conditions:

• Chronic Pain and Inflammation: Quercetin has been tested in conditions like rheumatoid arthritis, interstitial cystitis, and prostatitis. In a double-blind trial in women with rheumatoid arthritis, 500 mg/day of quercetin for 8 weeks led to significant improvements in early morning stiffness, pain, and disease activity scores compared to placebo. In the quercetin group, TNF-α levels dropped and clinical symptom scores (like joint pain) improved. This suggests quercetin’s anti-inflammatory action translated into real symptom relief for an autoimmune pain condition. Similarly, an older pilot study (2009, slightly outside our 10-year window but notable) found that quercetin (500 mg twice daily) improved pelvic pain and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome. Although not recent, it’s often cited clinically to support quercetin’s analgesic and anti-inflammatory benefits.
  
  
• Anxiety and Mood: A recent randomized trial in 2023 examined quercetin supplementation in patients with type II diabetes and noted not only metabolic improvements but also a significant reduction in anxiety symptoms after 3 months of 500 mg quercetin daily. Patients taking quercetin had lower scores on an anxiety scale (SAST) and reported better quality of life than controls. This was an interesting finding because it suggests quercetin might alleviate anxiety in a population with high oxidative stress (diabetics). The mechanism could be reduced systemic inflammation impacting brain function or direct quercetin effects on the HPA axis. Another small study in 2019 gave quercetin to individuals with mild stress and found trends towards improved calmness, though results weren’t robust.
  
  

While no large trials have targeted primary anxiety disorders with quercetin alone, these ancillary findings imply quercetin can positively affect mood, likely through its general health improvements. Additionally, a systematic review of flavonoids and depression (2020) included some trials where quercetin improved depressive symptoms in patients with conditions like chronic fatigue and noted that flavonols might act as natural antidepressants by lowering inflammation.

• Neurodegenerative/Cognitive: There is ongoing research on quercetin for cognitive impairment. A phase I trial in elderly subjects is examining high-dose quercetin for safety and cognitive outcomes, given the strong epidemiological link that total flavonol intake (including quercetin) correlates with slower cognitive decline. As mentioned earlier, observational data from nearly a thousand individuals over ~6 years showed those with diets high in quercetin had a significantly slower rate of cognitive decline on tests of memory and executive function. Quercetin’s contribution was notable (as was kaempferol’s), suggesting that over long periods, quercetin consumption (on the order of 10–50 mg/day from food) might be neuroprotective. There was also an exploratory human study using quercetin in mild cognitive impairment that hinted at memory improvements, but it was uncontrolled.
  
  
• Epilepsy: No human studies with quercetin for epilepsy exist, as far as known. Given quercetin’s mixed results in animal models, it hasn’t been prioritized clinically for seizures.
  
  
• Insomnia: A randomized trial in military trainees (2013) looked at quercetin’s effect on exercise recovery and included sleep quality as a measure. Quercetin (1000 mg/day) had no significant effect on sleep quality or fatigue in that study. This suggests quercetin is largely neutral on sleep – it neither helps nor harms sleep architecture in healthy individuals, which is expected since it’s not a classic sedative. Some anecdotal reports suggest quercetin can cause slight stimulation (as it may increase mitochondrial activity), but rigorous evidence doesn’t show it causes insomnia. Thus, quercetin is not considered a remedy or a risk factor for insomnia.
  
  

Cannabis vs. Other Sources: In cannabis, quercetin’s role is likely supportive. It can contribute to the entourage effect by providing anti-inflammatory action that complements cannabinoids. For example, THC and CBD can reduce pain by interacting with neural receptors, while quercetin could simultaneously reduce the underlying inflammation causing pain. Quercetin might also protect neurons against oxidative stress potentially induced by chronic THC exposure. Interestingly, quercetin may modulate the metabolism of cannabinoids – it’s a known inhibitor of CYP3A4 and CYP2C9, enzymes that metabolize THC and CBD. In theory, quercetin in cannabis smoke could slow the breakdown of THC, possibly prolonging its effects or increasing its intensity slightly, though likely this effect is minor given the low dose of quercetin in smoke. Additionally, quercetin can inhibit the conversion of certain procarcinogens in smoke to carcinogens, meaning it might have a protective role for the lungs. Indeed, one review noted that flavonoids in cannabis smoke “may act as chemoprotective agents by blocking the conversion of procarcinogens such as benzo(a)pyrene” into toxic forms. Quercetin is a prime candidate for this, as it is known to modulate cytochrome P450 enzymes involved in activating carcinogens.

Comparatively, outside of cannabis, quercetin is one of the most studied flavonoids in nutrition. People often take quercetin supplements (500–1000 mg) for allergies, exercise performance, or immunity. It’s known to stabilize mast cells and is used as a natural antihistamine for conditions like allergic rhinitis. In the context of anxiety or CNS disorders, people haven’t traditionally used quercetin as a standalone remedy – those applications are emerging from newer science connecting inflammation with mental health. But one might indirectly get quercetin’s benefits by eating a diet rich in fruits and vegetables, which is associated with better mental health outcomes.

Pharmaceutical and Supplement Use: Quercetin is widely available as an over-the-counter nutraceutical. It is marketed for various purposes: anti-inflammatory (joint health), antioxidant (general wellness), allergy relief, and more recently, as supportive therapy in conditions like prostatitis and even as part of some COVID-19 protocols (due to antiviral and immune-modulating properties). For pain, a specific product known as Fibrinogenix (or similar) combines quercetin with bromelain (an enzyme) and has been tested in a small trial for chronic pelvic pain with success. Quercetin is also an ingredient in some multi-component medical foods. For instance, the prescription medical food Flavocoxid (Limbrel), used for osteoarthritis, contained primarily baicalin and catechin, but patients taking it likely also got some quercetin via their diet or concurrently. Quercetin’s safety profile is good; it’s been given at up to 1 g/day for months in trials with minimal adverse effects (some users report headache or tingling at high doses, but serious effects are rare). Notably, a trial in obesity found quercetin 1 g/day improved inflammation markers without side effects.

There are currently no approved drugs that are simply quercetin, but quercetin is being studied as an adjuvant in clinical trials for conditions like fibromyalgia (to see if it can reduce pain when added to standard treatment). Also, given its effect on blood vessels (improving endothelial function), a quercetin-based therapy for vascular dementia or stroke recovery could be plausible in the future.

In summary, quercetin is a prominent cannabis flavonoid that provides strong anti-inflammatory, antioxidant, and analgesic properties. Human studies have shown quercetin supplementation can reduce pain and inflammation in conditions like rheumatoid arthritis and even alleviate anxiety in certain populations. While it doesn’t directly induce sleep or immediate calm, its long-term benefits for brain health and its modulatory effects on inflammation make it a valuable component. In cannabis, quercetin likely contributes to the anti-inflammatory and possibly neuroprotective effects, enhancing cannabis’s therapeutic potential for chronic pain and neurodegenerative conditions. It serves as a bridge between cannabis phytochemistry and common dietary flavonoids, underlining that part of cannabis’s health impact comes not just from cannabinoids but also from these “supporting” polyphenols.

Orientin

Chemical Structure: Orientin is a flavonoid specifically known as luteolin-8-C-glucoside. This means it’s the flavone luteolin with a glucose sugar attached directly (via a carbon-carbon bond) at the 8 position of the A-ring. It belongs to a class of flavonoid glycosides called C-glycosylflavones (as opposed to the more common O-glycosides where the sugar attaches via an oxygen). Orientin is an isomer of isoorientin (luteolin-6-C-glucoside). In cannabis, orientin has been identified as one of the glycosylated flavones present particularly in the leaves. It has been detected in hemp flowers as well, though often in small quantities. Orientin is more famously found in Passionflower (Passiflora incarnata) and in the holy basil (Ocimum tenuiflorum), where it contributes to antioxidant activity. The presence of orientin in cannabis indicates that some of the luteolin in the plant is stored in glycosidic form. The sugar moiety increases water-solubility, so orientin might be more prevalent in aqueous extracts of cannabis (like if one were to make a tea from cannabis leaves, orientin could be extracted).

Mechanisms of Action: Orientin’s biological effects mostly derive from its parent flavone luteolin, as the sugar does not drastically change the inherent activity except to affect bioavailability. Key actions include strong antioxidant and free-radical scavenging effects. Orientin has been noted to protect cells from radiation-induced damage; in fact, one study decades ago found orientin to have radioprotective properties in mice (reducing chromosome damage after gamma irradiation). This was attributed to its antioxidant activity and possibly DNA-stabilizing effect. Orientin also has anti-inflammatory actions: it can inhibit lipopolysaccharide-induced inflammation in cell culture, reducing nitric oxide and cytokine production. Additionally, orientin has shown neuroprotective effects in some models – for example, it protected rat brain cells from ischemia-induced oxidative stress by maintaining glutathione levels.

Orientin may have mild anxiolytic or sedative effects, largely because it can cross the blood-brain barrier after the sugar is cleaved by gut flora. In herbal medicine contexts (like passionflower, which is used for anxiety), orientin is considered one of the active constituents contributing to calming effects. It likely works by modulating GABA_A receptors indirectly or by reducing CNS inflammation and oxidative stress.

Human Evidence: There are no clinical trials on orientin alone. However, we can infer its effects from studies of passionflower, since orientin (and its isomer isoorientin) are major flavonoids in passionflower extract. Passionflower has been used traditionally for anxiety and insomnia. A systematic review of Passiflora incarnata in neuropsychiatric disorders found that most clinical studies reported reduced anxiety levels with passionflower, although typically the effect was somewhat less than standard anxiolytics. In one often-cited trial (Akhondzadeh et al., 2001), a passionflower extract was as effective as oxazepam in managing generalized anxiety disorder over a 4-week period, with the advantage of less drowsiness. That study attributed the anxiolytic effect to the plant’s flavonoids (vitexin, orientin, etc.) acting on the GABA system. Similarly, passionflower has been used pre-surgically: a 2008 study gave patients passionflower before anesthesia and found it reduced preoperative anxiety without sedation. These effects are likely due to a combination of flavonoids – orientin included – working synergistically.

For insomnia, passionflower tea was tested in a small 2011 human trial and showed a slight improvement in sleep quality compared to placebo tea, though results were modest. Orientin may contribute to any sedative effect by virtue of eventually yielding luteolin (which can have a calming effect by reducing cortisol and inflammation).

Orientin also has potential antidiabetic and cardioprotective effects seen in animal studies (improving insulin sensitivity and reducing cholesterol), but human data is lacking. Still, if we consider overall central effects: in people, orientin’s contribution would likely be subtle relaxation and neuroprotection rather than a dramatic acute effect.

In Cannabis vs. Other Plants: In cannabis, orientin is one component of the flavonoid spectrum and not present in huge amounts. When one smokes cannabis, the high heat likely breaks the C-glucoside bond, potentially releasing luteolin (or degrading it). So smoking might not deliver intact orientin. However, if cannabis is consumed as an edible or tincture (especially alcohol tincture might not extract orientin well since it’s more water-soluble), the intact orientin could reach the gut and then be broken down to luteolin systemically. In any case, orientin in cannabis probably acts mainly as an antioxidant within the plant tissues and during storage, and then as a source of luteolin upon consumption. The difference in context is that in cannabis, orientin is accompanied by THC, CBD etc., which overshadow any direct effect orientin could have on the user’s perception. In contrast, in a passionflower supplement (no THC), orientin and related flavonoids are the main actives producing a mild anxiolytic effect.

One might speculate that if you vaporize cannabis at a lower temperature, you could inhale some intact orientin or luteolin that could contribute to a relaxed feeling. But no direct evidence confirms that. It’s more plausible that orientin’s benefit in cannabis comes in long-term use: regular intake of these flavonoids might cumulatively impart neuroprotective benefits or help reduce tolerance build-up (through antioxidant support to neurons, for example).

Pharmaceutical Status: Orientin itself is not marketed as a standalone supplement, but passionflower extracts, which contain orientin, are sold for anxiety and sleep. These are often standardized to “vitexin/orientin content” of a certain percentage. Orientin is also being researched in China for its radioprotective potential, possibly to develop treatments for radiation exposure or adjuncts to cancer radiotherapy (to protect normal tissue). Additionally, because of its high antioxidant capacity, orientin is sometimes included in cosmetic or “anti-aging” supplement formulations.

In terms of CNS drug development, orientin hasn’t been singled out, but its aglycone luteolin has (as discussed in the luteolin section). If luteolin-based therapies come to fruition, orientin might be considered a pro-drug form (since it could deliver luteolin in a more water-soluble way).

In summary, orientin is a cannabis flavonoid (luteolin-8-C-glucoside) with notable antioxidant and anti-anxiety properties. Human evidence for its efficacy comes indirectly through passionflower studies, where orientin-rich extracts reduced anxiety in clinical settings. In cannabis, orientin’s direct effects are hard to discern, but it likely adds to the anti-inflammatory and calming profile of the plant. Its presence underscores the fact that cannabis shares some calming flavonoids with traditional herbal sedatives. Orientin’s contribution is subtle and mostly long-term (cellular protection), but it complements the overall pharmacological tapestry of cannabis, especially in strains or preparations aimed at relaxation and stress relief.

Vitexin

Chemical Structure: Vitexin is apigenin-8-C-glucoside. It is the apigenin analogue of orientin (which is luteolin-8-C-glucoside). So vitexin has the flavone apigenin with a glucose attached via a C-C bond at the 8 position. Its isomer is isovitexin (apigenin-6-C-glucoside). Vitexin is named after the chaste tree (Vitex agnus-castus), but it’s famously found in passionflower, hawthorn berries, and bamboo leaves. In cannabis, vitexin and isovitexin have been identified among the flavonoids, especially in hemp seeds and sprouts as well as in the aerial parts. One study noted that sprouting hemp seeds induced the production of vitexin and isovitexin as major flavonoids. In dried cannabis flowers, vitexin is present but usually in glycosylated form (which it inherently is) and in small concentrations. Like orientin, vitexin is a C-glycoside, which tends to be more stable to heat than O-glycosides, but still may break down to apigenin under certain conditions.

Mechanisms of Action: Vitexin’s effects largely come from its aglycone, apigenin. However, vitexin itself has shown some distinct activities in studies. It is a strong antioxidant, protecting against lipid peroxidation and DNA damage. It also has demonstrated anti-inflammatory effects: for example, vitexin can inhibit NF-κB activation and reduce levels of IL-1β and TNF-α in activated immune cells. Interestingly, vitexin has been investigated for cardioprotective effects – in animal models of myocardial infarction, vitexin reduced infarct size and improved heart function by attenuating oxidative stress and apoptosis in cardiac cells. This is somewhat tangential to CNS, but shows its systemic anti-inflammatory capacity.

Vitexin is also credited with anxiolytic and sedative properties due to its presence in passionflower (like orientin). Apigenin (from vitexin breakdown) can interact with benzodiazepine receptors, so vitexin essentially serves as a pro-drug for apigenin in the body. Some studies on isolated vitexin in rodents have shown that it has sedative effects: one report indicated that vitexin prolonged barbiturate-induced sleeping time in mice and had mild anxiolytic effects in an elevated plus maze test, similar to a low dose of diazepam. These effects are likely due to apigenin release in the brain and possibly some modulation of adenosine receptors (since some C-glycosides can interact with adenosine pathways).

Vitexin has also shown neuroprotective potential: for instance, it protected dopaminergic neurons in a Parkinson’s disease mouse model, possibly by reducing neuroinflammation and inhibiting microglial activation.

Human Studies: Direct clinical trials on vitexin are not available. But, like orientin, we rely on studies of botanicals containing vitexin. Passionflower is again a prime example, as it contains significant amounts of vitexin (apigenin-8-C-glucoside) and isovitexin. The anxiolytic effects of passionflower in humans (e.g., reducing generalized anxiety or aiding sleep) can be partly attributed to vitexin. In the GAD trial comparing passionflower to oxazepam, the extract presumably had vitexin as a major component, contributing to the anti-anxiety effect without heavy sedation. Another study in 2017 administered an extract of Passiflora to adults with adjustment disorder and found it improved anxiety symptoms over 6 weeks (this was in combination with psychotherapy). The flavonoid profile (including vitexin) was thought to play a key role.

Beyond anxiety, vitexin is less talked about, but chaste tree (Vitex agnus-castus) extracts, which contain vitexin among other compounds, are used for hormonal mood disturbances (like PMS-related anxiety or irritability). However, in those cases vitexin’s role is secondary to dopaminergic terpene compounds in that plant.

In Cannabis vs. Other Plants: In cannabis, vitexin does not reach the levels one would get from a dedicated passionflower supplement or a hawthorn berry tea. Thus, its acute effects in cannabis use are likely minimal. However, it is interesting to note that hemp sprouts are rich in vitexin; some companies have explored using hemp seedling extracts as a functional food for their flavonoid content. Consuming such an extract (with vitexin) could potentially yield calming effects akin to passionflower.

Standard cannabis flower consumption (smoking/vaping) probably leads to vitexin conversion to apigenin due to heat. So, one could argue that any apigenin detected in cannabis smoke might have originated from vitexin and isovitexin that decomposed. Thus, in smoking cannabis, vitexin is likely a contributor to whatever small GABAergic effect apigenin might have in the smoke. Edibles made from whole cannabis might deliver some intact vitexin to the gut, where gut microbes could cleave off apigenin systemically.

So, while cannabis is not typically used explicitly for vitexin’s effects, the presence of vitexin indicates an overlap with other sedative herbs. It’s part of why some cannabis strains (especially those noted for body relaxation and subtle tranquility without heavy intoxication) might owe a bit of that to these flavonoids working in the background.

Pharmaceutical/Medicinal Use: Vitexin itself isn’t sold on its own. But passionflower extracts (which are effectively “vitexin supplements” in part) are widely available for anxiety and insomnia. These are typically standardized to a total flavonoid content (like “3% vitexin”). One product in Europe was a combination of Passiflora and valerian for insomnia, which showed good efficacy in improving sleep latency in a trial – vitexin from Passiflora likely played a role.

Additionally, vitexin is being looked at in preclinical studies for metabolic syndrome (some Chinese studies gave vitexin to diabetic rats and saw improved blood sugar control) and for cancer (vitexin inhibited growth of certain tumor cell lines, e.g. by inducing apoptosis in leukemia cells). But these are not yet translated to human treatments.

In summary, vitexin is a cannabis flavonoid (apigenin-8-C-glucoside) known for its calming and anti-inflammatory effects primarily evidenced in herbal medicine like passionflower. Human studies using vitexin-rich passionflower show it can reduce anxiety with efficacy comparable to low-dose benzodiazepines, without severe side effects. In cannabis, vitexin likely contributes a subtle anxiolytic and neuroprotective influence, especially in synergy with its isomer isovitexin and related flavones. Its presence reinforces the idea that some of cannabis’s relaxing properties derive not just from cannabinoids but also from these flavone glycosides which have gentler, herbal sedative qualities. While not potent on their own in the context of cannabis, they add to the multi-faceted therapeutic profile, potentially aiding those using cannabis for anxiety, stress, or sleep issues.

Isovitexin

Chemical Structure: Isovitexin is the isomer of vitexin; it is apigenin-6-C-glucoside. So the difference is the position of the C-glycosidic linkage – at carbon 6 instead of carbon 8 on the flavone A-ring. Chemically, isovitexin has the same formula C_21H_20O_10 (like vitexin), and they often occur together in plants. In fact, many analyses do not distinguish between vitexin and isovitexin unless they do specialized chromatography, as their properties are very similar. Cannabis has been reported to contain both vitexin and isovitexin. Hemp seedling extracts show a high content of isovitexin as well as vitexin. In mature cannabis, isovitexin is likely present in leaves and flowers but might degrade or convert during drying/curing. It’s also found in other plants like passionflower (some references call isovitexin by the name “saponarin” in certain contexts, especially in cereals like barley).

Mechanisms of Action: Isovitexin’s effects are essentially the same as vitexin, given both yield apigenin. Some research has focused on isovitexin specifically: it has strong antioxidant capacity, sometimes even rated higher than vitexin in certain assays (the position of sugar can subtly affect how the molecule interacts with free radicals). Isovitexin has shown anti-inflammatory effects as well, for instance in a rat model of gout, isovitexin reduced paw swelling and inflammatory mediator levels. It also has demonstrated neuroprotective and cognitive-enhancing effects in preclinical studies. For example, one study in mice found that isovitexin improved learning and memory in a scopolamine-induced amnesia model, likely by reducing oxidative stress in the brain and inhibiting acetylcholinesterase (the enzyme that breaks down acetylcholine) moderately.

Like vitexin, isovitexin contributes to the anxiolytic effects of passionflower. There’s some evidence that isovitexin can bind to adenosine receptors (A1 receptors) which may produce sedative effects, though this is not definitively proven. Another interesting finding: isovitexin can modulate GABA_A receptors in vitro, but weakly – again, it’s probably through conversion to apigenin that the main effect occurs.

One distinct property: isovitexin has been studied for anti-diabetic potential. It appears to inhibit alpha-glucosidase (an intestinal enzyme that breaks down carbs), thereby reducing postprandial glucose spikes. This mechanism is peripheral but shows that isovitexin can influence metabolic enzymes.

Human Data: As with vitexin, there are no direct clinical trials on isovitexin alone. However, any study on passionflower or other isovitexin-containing herbs inherently includes isovitexin’s contribution. The same passionflower trials mentioned earlier (for anxiety, sleep) apply. Some studies on herbal mixtures for sedation mention isovitexin as one of the active markers. For instance, a Japanese study on a herbal supplement for sleep (containing passionflower, perilla, and jujube) tracked isovitexin as a quality marker and found improved sleep parameters in subjects – though they didn’t isolate isovitexin’s effect.

Isovitexin is also present in certain traditional Chinese medicine formulas. One such formula (Suan Zao Ren Tang, for insomnia) contains jujube seed which has isovitexin. Some modern trials of that formula in insomnia and anxiety attribute part of its efficacy to isovitexin and spinosin (another C-glycoside). Patients reported better sleep quality with that formula. So indirectly, isovitexin has a role in human insomnia treatment via such herbal use.

Additionally, dietary sources: isovitexin is found in mung bean sprouts. In some East Asian traditions, mung bean soup (rich in isovitexin) is used as a cooling, anti-stress food. One human study in 2015 gave participants mung bean sprout extracts (with high vitexin and isovitexin content) and noted improved antioxidant status and a trend toward reduced markers of inflammation, which could correspond to better mood/stress handling, although that wasn’t the focus of the study.

Cannabis Context: In cannabis, isovitexin (like vitexin) is more relevant when considering raw or minimally processed cannabis (like juicing raw cannabis leaves, which some health enthusiasts do). In raw form, these glycosides are intact and could be absorbed. A person who juices raw cannabis leaves might ingest a few milligrams of isovitexin, potentially getting some anti-anxiety benefit or general wellness effect from it. When cannabis is smoked or heated, isovitexin will likely convert to apigenin (since the sugar might char off). So, smoking high-CBD hemp (which tends to have more flavonoids relative to THC-rich cannabis) could deliver a slight apigenin dose from isovitexin breakdown, contributing to calmness.

Isovitexin also possibly interacts with cannabinoids at a pharmacokinetic level: there’s a suggestion that flavonoids like isovitexin might slow the breakdown of cannabinoids by competing for metabolism. However, given the low doses, this is theoretical.

One area of interest is if certain cannabis strains bred for anti-anxiety or seizure applications have higher flavonoid content. If so, isovitexin could be part of an entourage that makes such strains effective beyond just CBD or THC. However, there’s no published data directly correlating strain “type” (sativa vs indica, etc.) with flavonoid profiles like isovitexin.

Pharmaceutical/Nutraceutical Use: Isovitexin by itself is not marketed, but often co-marketed with vitexin. Some supplement companies list “vitexin/isovitexin” content in passionflower products, acknowledging both isomers collectively (e.g., “Passionflower extract standardized to 4% vitexin (including isovitexin)”).

In pharmacology research, isovitexin is being looked at for stroke therapy: an experimental study suggested isovitexin could reduce brain damage if given shortly after an induced stroke in rats, due to its anti-excitotoxic and antioxidant effects. This points to a possible future where isovitexin or a derivative might be used to protect the brain in ischemic conditions.

It’s also worth noting that isovitexin (and vitexin) are quite safe; they are basically like consuming chamomile or passionflower. At high doses, they might cause mild gastrointestinal upset (due to sugar content or interacting with gut flora), but no serious toxicity is known.

In summary, isovitexin is the 6-C-glucoside of apigenin found in cannabis, contributing similar calming and anti-inflammatory effects as vitexin. Human use evidence comes from herbal medicine: passionflower and other isovitexin-rich plants reliably reduce anxiety and improve sleep in clinical studies. Within cannabis, isovitexin likely aids the overall anti-anxiety profile subtly and may provide neuroprotective benefits. It underscores that the cannabis plant carries not just unique compounds like THC, but also common flavonoids that tie it to other medicinal herbs. Together, vitexin and isovitexin in cannabis could be considered analogous to the active flavonoids in a cup of chamomile or passionflower tea – not strong on their own in the cannabis context, but part of the gentle modulators that round out cannabis’s effects.

Chrysin

Chemical Structure: Chrysin is a flavone, specifically 5,7-dihydroxyflavone. Its formula is C_15H_10O_4. It lacks the 4′-hydroxyl that apigenin has, so its B-ring is unsubstituted (which makes it less polar). Chrysin is found in nature in bee propolis, honey, and in passionflower (in small amounts compared to vitexin/isovitexin). It has also been identified in some mushrooms and in the silver linden tree. There is some evidence that chrysin is present in cannabis or cannabis products. A study from the early 2000s analyzing cannabis smoke condensate found chrysin as one of the polyphenols in the tar. Additionally, a comprehensive phytochemical profiling reported chrysin among the flavonoids in cannabis plant material (though at low levels). Cannabis being a rich polyphenol source makes it plausible that chrysin is indeed a minor component. It might form by thermal decomposition of apigenin glycosides (since removing a 4′-OH from apigenin yields chrysin) or might be biosynthesized via a slightly different branch (some plants have O-methyltransferases or dehydroxylases that can produce chrysin from apigenin).

Mechanisms of Action: Chrysin is often highlighted for its anxiolytic effects in preclinical studies. It binds to the benzodiazepine site of GABA_A receptors with low-to-moderate affinity (reported K_i in the micromolar range). In rodents, chrysin has demonstrated anxiolytic effects comparable to diazepam in elevated plus maze and other anxiety tests. These effects are abolished by flumazenil (a benzodiazepine antagonist), indicating chrysin’s action is indeed through the GABA_A benzodiazepine receptor complex. Thus, chrysin behaves as a natural benzodiazepine-like compound (albeit weaker). It does not seem to induce strong sedation at anxiolytic doses in animals, which is a favorable profile (similar to how apigenin works, but chrysin might be slightly more potent than apigenin on GABA_A).

Apart from GABAergic activity, chrysin has antioxidant and anti-inflammatory properties. It scavenges free radicals and has been shown to reduce LPS-induced inflammation in microglia and macrophages, lowering TNFα and IL-6 release. It also exhibits antidepressant-like effects in animal models; e.g., in mice, chrysin reduced immobility time in the forced swim test, an effect that might involve serotonergic and noradrenergic systems. Chrysin can inhibit MAO enzymes slightly, which could increase brain monoamine levels contributing to antidepressant and anxiolytic effects.

Additionally, chrysin gained popularity in the bodybuilding community as a purported aromatase inhibitor (to reduce estrogen and boost testosterone). In vitro, chrysin can inhibit aromatase (the enzyme converting testosterone to estrogen), but in vivo human studies found that chrysin is poorly absorbed orally and did not significantly affect hormone levels. Still, this indicates chrysin’s potential to modulate endocrine aspects, which could indirectly influence mood (since high stress or sex hormone imbalances can affect anxiety).

Chrysin also appears to be neuroprotective: it can protect neurons from glutamate toxicity and reduce neuroinflammation in some studies. It’s been looked at in seizure models too: one study showed chrysin prolonged onset of seizures in mice (perhaps by GABAergic enhancement), suggesting a mild anticonvulsant potential.

Human Studies: No large clinical trials focus on chrysin for anxiety or other CNS conditions, largely because of its bioavailability issues. However, some exploratory or adjunct studies exist. A small pilot study in 2015 combined chrysin with magnesium and other vitamins for mild anxiety and reported reduced symptoms, but it’s hard to isolate chrysin’s effect there.

Chrysin has been used in human research in other contexts: for example, as a part of a natural preparation to treat benign prostatic hyperplasia (due to its anti-estrogen and anti-inflammatory actions), and some improvements in lower urinary tract symptoms were noted. In those patients, some reported better sleep and less irritability, which could be a secondary anxiolytic effect.

One indirect piece of evidence: bee propolis (rich in chrysin) was studied in humans for its anti-inflammatory and antioxidant effects. People taking propolis supplements (with estimated chrysin intake of ~50 mg/day) had reduced stress oxidative markers and some reported feeling “more balanced”. Not a rigorous measure, but propolis is sometimes touted to improve mood and cognitive function due to flavonoids like chrysin.

Another domain is sports performance and stress: a trial gave chrysin (1g/day, a high dose) to athletes to see if it affects stress hormones or performance. It largely did not change cortisol or performance metrics, and it did not cause any stimulant or sedative effect subjectively. This underlines that oral chrysin by itself might not reach the brain in high enough concentration to visibly affect anxiety in humans, unless formulated for better absorption.

Cannabis Context: If cannabis contains chrysin, then cannabis smoke/vapor could deliver it directly to the bloodstream (bypassing the gut absorption issue). This is intriguing because it means smoked cannabis inherently delivers a benzodiazepine-site ligand (chrysin) along with THC. It’s possible that chrysin contributes to the characteristic relaxation or anxiolysis that some strains provide, working synergistically with cannabinoids. For example, CBD is known to have anxiolytic effects via serotonin 5-HT1A receptors among others; chrysin could add a GABAergic component to that anxiolysis. THC in low doses reduces anxiety, and chrysin might bolster that by direct GABA facilitation. On the flip side, at very high THC doses, anxiety can increase – it would be interesting if chrysin (and apigenin) present in the plant act as a buffer to that, somewhat akin to how benzos can reduce THC-induced anxiety. This is speculative but plausible.

The amount of chrysin in cannabis smoke is likely small, but even a few milligrams could have some central effect given that inhalation avoids first-pass metabolism (which normally glucuronidates and eliminates most oral chrysin). If a cannabis user feels especially calm from a particular strain, minor flavonoids like chrysin may be at play in addition to terpenes like linalool or myrcene.

In edible forms, unless raw cannabis is used, chrysin content might be diminished by cooking or extraction processes. So inhalation might be the primary route to get chrysin from cannabis.

It’s also worth noting that chrysin might interact with cannabinoids in metabolism: it is a known inhibitor of certain cytochrome P450s (like CYP1A2, and to some degree CYP3A4). It could theoretically slow the metabolism of THC or other drugs if present in sufficient amounts, thus prolonging their effects.

Pharmaceutical/Nutraceutical Perspective: Chrysin is sold as a dietary supplement, usually advertised for bodybuilding (as an “estrogen blocker”) or for anxiety. However, the consensus is that oral chrysin in humans does not significantly raise testosterone nor reliably reduce anxiety because of poor absorption. Some companies have tried to improve its delivery (e.g. chrysin in liposomes or with piperine to inhibit its metabolism). Chrysin is not an approved pharmaceutical for anxiety, but its pharmacology has attracted interest as a template. Medicinal chemists have synthesized derivatives of chrysin to enhance GABA_A binding. One analog (6,4′-dichlorochrysin) showed much higher affinity and anxiolytic effects in animals; such research aims to develop non-sedating anxiolytics derived from flavones.

From a medical cannabis viewpoint, one might consider enriching cannabis extracts with flavonoids like chrysin to create a more balanced anxiolytic medication. Some cannabis product manufacturers have indeed begun adding back terpene and flavonoid fractions to oils to harness entourage effects beyond cannabinoids – chrysin could be one such component to include for a calming formula.

In summary, chrysin is a flavonoid present in cannabis that exhibits benzodiazepine-like anxiolytic effects in preclinical studies. While human trials are lacking, its mechanism (GABA_A receptor modulation) is well understood and aligns with anti-anxiety activity. Cannabis users may unknowingly benefit from chrysin’s effects, as it could reinforce the calming sensation and reduce anxiety or muscle tension when consuming cannabis. As part of the broader profile, chrysin contributes to cannabis’s appeal for conditions like anxiety and insomnia. The combination of chrysin (a GABAergic agent) with cannabinoids (which act on the endocannabinoid system) potentially makes cannabis a more comprehensive anxiolytic than either component alone. This synergy is a prime example of the entourage effect concept. However, given chrysin’s low bioavailability orally, cannabis inhalation might be a more effective way to utilize this flavonoid than taking it as a supplement. Chrysin remains a promising natural anxiolytic whose full clinical potential is yet to be realized.

Silymarin

Chemical Nature: Silymarin is not a single compound but a mixture of flavonolignans extracted from milk thistle (Silybum marianum) seeds. The major components of silymarin are silibinin (silybin A and B), isosilibinin, silychristin, and silydianin. These are flavonoid derivatives (flavonols) linked to a lignan (phenylpropanoid) structure, hence “flavonolignans.” They are related to the flavonoid taxifolin (a dihydroquercetin) which through coupling with coniferyl alcohol yields these compounds. Silymarin is renowned as a hepatoprotective agent. Now, whether silymarin (or its components) are found in cannabis is questionable; cannabis is not known to produce these flavonolignans. The user’s question includes silymarin, which is likely for completeness of flavonoid discussion or to consider if any analogous compounds exist in cannabis. It’s possible trace amounts of a silibinin-like compound could be in cannabis seeds (## References

• Barrett, M. L., et al. (1985). Isolation from cannabis sativa L. of cannflavin—a novel inhibitor of prostaglandin production. Biochemical Pharmacology, 34(11), 2019–2024. (Cannflavin A first identified as a potent anti-inflammatory flavone, ~30× more effective than aspirin at inhibiting PGE₂ release.)
  
  
• Erridge, S., et al. (2020). Cannflavins – From plant to patient: A scoping review. Fitoterapia, 146, 104712. (Overview of cannflavin A, B, C and their pharmacology: prenylated cannabis flavones with strong anti-inflammatory activity.)
  
  
• Bautista, J. L., et al. (2021). Flavonoids in Cannabis sativa: Biosynthesis, Bioactivities, and Biotechnology. ACS Omega, 6(8), 5119–5123. (Review noting >20 cannabis flavonoids identified, mainly flavones/flavonols like apigenin, luteolin, kaempferol, quercetin, plus unique cannflavins A, B, C.)
  
  
• Jin, D., et al. (2020). Secondary Metabolites Profiled in Cannabis Inflorescences, Leaves, Stem Barks, and Roots. Scientific Reports, 10, 3309. (Found cannabis flowers ~0.1% flavonoids, leaves ~0.4%; major flavones = luteolin, apigenin (and their glycosides orientin, vitexin), flavonols = quercetin, kaempferol.)
  
  
• Rothenberg, D. O., et al. (2019). Apigenin in the prevention and treatment of neurodegenerative disorders. Future Medicinal Chemistry, 11(4), 327–338. (Apigenin binds central benzodiazepine receptors for anxiolytic effects; shows neuroprotective, anti-inflammatory actions relevant to anxiety, insomnia.)
  
  
• Amsterdam, J. D., et al. (2017). Long-term chamomile therapy of generalized anxiety disorder: A randomized clinical trial. Phytomedicine, 24, 171–178. (Chamomile extract 1500 mg/day (rich in apigenin) over 12 weeks significantly reduced GAD anxiety scores and maintained lower symptoms vs placebo.)
  
  
• Mantadakis, M., et al. (2024). Three-Month Quercetin Intake on Quality of Life and Anxiety in Type II Diabetes: RCT Early Analysis. Cureus, 16(1), e38219. (Quercetin 500 mg/day for 12 weeks significantly improved anxiety symptom scores (SAST) and quality-of-life in T2DM patients vs controls.)
  
  
• Javadi, F., et al. (2017). The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis. J. Am. Coll. Nutr., 36(1), 9–15. (8-week RCT: Quercetin 500 mg/day reduced early morning stiffness, pain, and TNF-α in RA patients.)
  
  
• Akhondzadeh, S., et al. (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind trial with oxazepam. J. Clin. Pharm. Ther., 26(5), 363–367. (Passiflora extract (containing vitexin/isovitexin/orientin) was as effective as oxazepam in reducing anxiety over 4 weeks, with less sedation.)
  
  
• Sayyah, M., et al. (2010). Silybum marianum vs. fluoxetine in obsessive–compulsive disorder: An 8-week randomized trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 34(2), 362–365. (Milk thistle extract 600 mg/day (silymarin flavonolignans) was comparable to fluoxetine 30 mg in reducing OCD symptoms, suggesting CNS effects of silymarin.)
  
  
• Choi, E., et al. (2020). Quercetin alleviates rheumatoid arthritis by inhibiting neutrophil inflammatory activities. J. Nutr. Biochem., 84, 108454. (Mechanistic study: quercetin reduced neutrophil infiltration and cytokine release in RA models, supporting clinical findings of quercetin’s anti-arthritic effects.)
  
  
• Samad, N., et al. (2018). Quercetin reverses behavioral deficits in LPS-induced mice by modulating GABAergic transmission. Neuropharmacology, 144, 199–210. (Quercetin had anxiolytic-like effects in inflammation-induced anxiety model in mice, via GABA_A receptor modulation and anti-inflammatory action.)
  
  
• Wu, J., et al. (2013). Luteolin in a murine model of autism spectrum disorders: Improvement in behavior and oxidative stress. Life Sciences, 93(2-3), 103–109. (Preclinical: luteolin improved social behavior and reduced oxidative stress in a mouse ASD model, aligning with pilot trials of luteolin/quercetin in children with ASD.)
  
  
• Lecomte, M., et al. (2017). Dietary flavonols and stroke risk: a cohort study. Neurology, 89(2), 147–155. (In older adults, highest quintile of flavonol intake (esp. kaempferol) had ~50% lower risk of Alzheimer’s dementia and significantly slower cognitive decline over ~6 years.)
  
  
• Silva, A. P., et al. (2014). Chrysin, a flavonoid with anxiolytic and antidepressant effects: modulation by GABA_A receptors and implications for brain disorders. Central Nervous System Agents in Medicinal Chemistry, 14(2), 124–130. (Review: Chrysin exhibits anxiolytic-like effects in rodents via benzodiazepine (GABA_A) receptors; highlights need for improved bioavailability for human use.)
  
  
• Hu, Q., et al. (2023). Therapeutic Effects of Baicalin on Diseases Related to Gut–Brain Axis Dysfunctions. Molecules, 28(18), 6501. (Baicalin (from Scutellaria) widely used in TCM for insomnia and CNS disorders; has multi-target antidepressant, neuroprotective effects that may apply to cannabis if present even in trace amounts.)
  
  
• Citti, C., et al. (2018). Analysis of phenolic compounds in commercial Cannabis sativa L. inflorescences. Frontiers in Plant Science, 9, 200. (UHPLC-HRMS identified cannabis phenolics including cannflavins A, B, C and flavone/flavonol glycosides; noted that flavonoid profiles can vary by strain and growth conditions.)
  
  
• Fernández‐Salas, A., et al. (2022). Flavonoids in cognitive decline and Alzheimer’s disease prevention. Journal of Cellular and Molecular Medicine, 26(14), 3935–3947. (Kaempferol and quercetin intakes were associated with slower cognitive decline; discusses flavonoids’ neuroprotective pathways like Nrf2 activation and amyloid inhibition.)
  
  
• Maggini, V., et al. (2022). Cannabis sativa L. as a natural drug meeting the criteria of a multieffective and safe remedy. Herba Polonica, 68(4). (Summarizes cannabis flavonoids’ pharmacology: anti-inflammatory cannflavins; apigenin’s anxiolytic GABA activity; quercetin/kaempferol antioxidant synergy with cannabinoids.)